Global Search

Search articles, concepts, and chapters

Curr Opin OphthalmolDecember 19985 citations

Ischemic optic neuropathy and giant cell arteritis.

McFadzean R M


AI Summary

This abstract discusses urgent treatment for arteritic ischemic optic neuropathy (AION) and challenges in non-arteritic AION (NAION) due to poor blood flow measurement and treatment options, exploring new therapies for both.

Abstract

Acute loss of vision due to anterior ischemic optic neuropathy, both arteritic and nonarteritic, demands investigation and where indicated, treatment as an emergency. While advances continue in the understanding of the pathophysiology and investigation of arteritic anterior ischemic optic neuropathy, the nonarteritic form presents a major therapeutic problem, particularly in the absence of a satisfactory clinical technique for the measurement of optic nerve head blood flow. Because of steroid resistance and side effects of chronic steroid therapy in giant cell arteritis, alternative immunosuppressive agents are being explored. In nonarteritic ischemic optic neuropathy, etiologic factors such as activated protein C resistance raise the possibility of evaluation for prothrombotic states, while calcium channel blockers offer prospects for the relief of ischemic effects at the cellular level.


MeSH Terms

AnimalsAnti-Inflammatory Agents, Non-SteroidalBlindnessDiagnosis, DifferentialGiant Cell ArteritisGlucocorticoidsHumansImmunosuppressive AgentsOptic Neuropathy, IschemicVisual Acuity

Is this article assigned to the wrong chapter(s)? Let us know.